Muscular Dystrophy Canada Rare Disease Day Update
Rare Disease Day, which occurs on the last day of February (Feb 28th, 2021), is meant to raise awareness amongst the general public and decision-makers about rare diseases and their impact on individuals’ lives. This year, Rare Disease Day will look a little different around the world as we connect virtually instead of in person due to the ongoing COVID-19 pandemic.
Considering many neuromuscular conditions are considered rare, and even ultra-rare, Muscular Dystrophy Canada (MDC) will be featuring individuals with lived experience with varying neuromuscular disorders.
In the week leading up to Rare Disease Day, each day MDC will spotlight a client and their response to the question: how has it been living with a NMD in the midst of the COVID-19 pandemic? These personal stories will showcase the diversified impact of the pandemic on the quality of lives of individuals affected by neuromuscular conditions and reveal individuals’ experiences with interrupted care, increased social isolation/fatigue, frequent cancellation or postponement of treatments and clinic visits, allied health and primary care or specialist appointments, and interrupted rehabilitation and home care supports.
The stories will also highlight the resilience of individuals and their families, the benefits of virtual tele-care and programs for those with mobility challenges and the positive lessons the pandemic has offered. In addition to the personal stories, to increase awareness and knowledge of NMDs, there will be a short plain-language descriptions of the following groups that fall within MDC’s umbrella:
(1) Muscular Dystrophies
(2) Congenital Muscular Dystrophies
(3) Congenital Myopathies
(4) Auto-immune Mediated Myopathies
(5) Metabolic Myopathies
(6) Genetic and Immune-Mediated Neuromuscular Junction Disorders
(7) Hereditary Peripheral Nerve Disorders (Genetic Neuropathies)
(8) Immune-Mediated Peripheral Nerve Disorders
(9) SMA and related Disorders
For more information about Rare Disease Day, please email
Return to the February 2021 Newsletter
Read next...
NMD4C Receive Excellence in Service Delivery Award and Network Investigators Honored as part of Muscular Dystrophy Canada’s 2024 Dr David Green Awards
We are excited to share that the NMD4C has been awarded the Excellence in Service Delivery Award, one of the annual Dr David Green Awards presented by Muscular Dystrophy Canada.
NMD4C Launch Canadian Neuromuscular Clinical Trial Network
We are thrilled to announce the launch of a Canadian neuromuscular clinical trial network (CTN) as a part of our clinical research work.
Training Session for Physiotherapists and Occupational Therapists on Outcome Measures in Spinal muscular atrophy hosted by Quebec SMA Network
This past March 23, the Quebec SMA Network (Réseau québécois de l’amyotrophie spinale – RQAS) in collaboration with the NMD4C and Muscular Dystrophy Canada (MDC) hosted an interactive training session for French-speaking physiotherapists and occupational therapists on assessment measures and practices for Spinal muscular atrophy (SMA). This training gathered clinicians to train and discuss SMA standardized outcome measures and work through current problems/challenges, to improve how these measures often tied to drug reimbursement are conducted.
MDC Announce Recipients of 2024 Neuromuscular Clinical and Translational Research Grants
Muscular Dystrophy Canada (MDC) recently announced the recipients of its annual Neuromuscular Research Grants competition. Through these grants, MDC is investing $900,000 into clinical and translational research projects.
SMA Outcome Measures Training for Physiotherapists and Occupational Therapists
To support the development and training on validated NMD outcome measures we are pleased to provide opportunities for physiotherapists and occupational therapists to attend training sessions for outcome measures.
Congratulations to the 2024 NMD4C Early Career Awards Recipients
We are excited to announce the recipients of the 2024 NMD4C Early Career Awards! This is the second year of our annual award program, celebrating excellence and contribution to the neuromuscular field from early career investigators across both clinical and basic science streams.